Viamet Pharmaceuticals Announces Appointment Of Amir Tavakkol, Ph.D., As Chief Development Officer
7/22/2014 10:24:59 AM
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Viamet Pharmaceuticals, Inc. today announced the appointment of Amir Tavakkol, Ph.D., as Chief Development Officer. Dr. Tavakkol brings over 25 years of experience in pharmaceuticals, consumer healthcare and academia, including substantial expertise in the clinical development of novel antifungal products for superficial as well as systemic indications. Dr. Tavakkol will have significant responsibility for the management of Viamet’s clinical programs, including the ongoing clinical development of VT-1161, the Company’s lead novel, oral antifungal compound. The Company plans to begin Phase 2b trials of VT-1161 for recurrent vulvovaginal candidiasis and onychomycosis in the second half of 2014.
Help employers find you! Check out all the jobs and post your resume.
comments powered by